Covaxin Next Phase Clinical Trials For 2 To 18 Age Group To Begin May 12, 2021, 13:26 IST
India battling the second wave of the coronavirus pandemic with a record surge in daily cases and deaths due to COVID-19. In the second wave, children below the age of 18 years and newborns have tested positive for COVID-19 in some parts of India. Now, experts are predicting that the third wave is just a few months aways and children are likely to get infected with the virus. There are chances that they can be diagnosed with mucormycosis fungal infection after contracting the virus.
Till now, the government announced that those who have crossed 18 years of age can get vaccine. Bharat Biotech on Tuesday was recommended by an expert panel to send its COVID-19 vaccine Covaxin for phase II and phase III clinical trial on children in between the age of 2 to 18 years.
Bharat Biotech s Covaxin recommended by expert panel for phase 2/3 trials on 2-18 year-olds yourstory.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yourstory.com Daily Mail and Mail on Sunday newspapers.
New Delhi:
Covaxin Phases 2 & 3 Clinical Trials for Children: Official sources said that Covaxin, the COVID-19 vaccine developed by Bharat Biotech s in collaboration with the Indian Council of Medical Research (ICMR), was on Tuesday recommended by an expert panel for phase-2 and phase-3 clinical trials on those aged between 2 and 18 years.
Sources said that the trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.
The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) on Tuesday deliberated upon Hyderabad-based Bharat Biotech s application, seeking permission to conduct phase II/III clinical trials to evaluate the safety, reactogenicity and immunogenicity of Covaxin jabs in children aged 2 to 18 years.
Covaxin has been developed by Hyderabad-based Bharat Biotech.
New Delhi:
Bharat Biotech s COVID-19 vaccine Covaxin was on Tuesday recommended by an expert panel for phase-2 and phase-3 clinical trials on those aged between two to 18 years, official sources said.
The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.
The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) on Tuesday deliberated upon Hyderabad-based Bharat Biotech s application, seeking permission to conduct phase II/III clinical trials to evaluate the safety, reactogenicity and immunogenicity of Covaxin jabs in children aged 2 to 18 years.